Tarsus Pharmaceuticals Total Assets 2020-2024 | TARS

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Tarsus Pharmaceuticals total assets from 2020 to 2024. Total assets can be defined as the sum of all assets on a company's balance sheet.

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Tarsus Pharmaceuticals total assets from 2020 to 2024. Total assets can be defined as the sum of all assets on a company's balance sheet.

Related Stocks
Company Name	Market Cap
Amgen (AMGN)	$178.9B
Regeneron Pharmaceuticals (REGN)	$125.5B
Vertex Pharmaceuticals (VRTX)	$122.4B
Gilead Sciences (GILD)	$104.4B
Bristol Myers Squibb (BMY)	$100.8B
CSL (CSLLY)	$96.8B
GSK (GSK)	$87.9B
Alnylam Pharmaceuticals (ALNY)	$35.1B
Argenex SE (ARGX)	$31.6B
Biogen (BIIB)	$28.8B
BioNTech SE (BNTX)	$27.5B
Moderna (MRNA)	$26.9B
Illumina (ILMN)	$20.9B
BeiGene (BGNE)	$19.2B
Genmab (GMAB)	$17.3B
BioMarin Pharmaceutical (BMRN)	$13.5B
Vaxcyte (PCVX)	$13B
Exact Sciences (EXAS)	$12.8B
Incyte (INCY)	$12.6B
Insmed (INSM)	$12.5B
Bio-Techne Corp (TECH)	$12.1B
Sarepta Therapeutics (SRPT)	$11.9B
QIAGEN (QGEN)	$10.4B
Bio-Rad Laboratories (BIO.B)	$9.1B
Legend Biotech (LEGN)	$9.1B
Roivant Sciences (ROIV)	$8.9B
Ascendis Pharma (ASND)	$8.7B
Repligen (RGEN)	$8B
Halozyme Therapeutics (HALO)	$7.9B
Intra-Cellular Therapies (ITCI)	$7.9B